|
1.
|
Mamane Y, Heylbroeck C, Genin P, Algarte
M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R and Hiscott J:
Interferon regulatory factors: the next generation. Gene. 237:1–14.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Taniguchi T, Ogasawara K, Takaoka A and
Tanaka N: IRF family of transcription factors as regulators of host
defense. Annu Rev Immunol. 19:623–655. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Wathelet MG, Lin CH, Parekh BS, Ronco LV,
Howley PM and Maniatis T: Virus infection induces the assembly of
coordinately activated transcription factors on the IFN-beta
enhancer in vivo. Mol Cell. 1:507–518. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Meraro D, Hashmueli S, Koren B, Azriel A,
Oumard A, Kirchhoff S, Hauser H, Nagulapalli S, Atchison ML and
Levi BZ: Protein-protein and DNA-protein interactions affect the
activity of lymphoid-specific IFN regulatory factors. J Immunol.
163:6468–6478. 1999.PubMed/NCBI
|
|
5.
|
Lohoff M and Mak TW: Roles of
interferon-regulatory factors in T-helper-cell differentiation. Nat
Rev Immunol. 5:125–135. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Nobuyuki T and Tadatsugu T: The interferon
regulatory factors and oncogenesis. Semin Cancer Biol. 10:73–81.
2000. View Article : Google Scholar
|
|
7.
|
Fujita T, Sakakibara J, Sudo Y, Miyamoto
M, Kimura Y and Taniguchi T: Evidence for a nuclear factor(s),
IRF-1, mediating induction and silencing properties to human
IFN-beta gene regulatory elements. EMBO J. 7:3397–3405. 1988.
|
|
8.
|
Mamane Y, Grandvaux N, Hernandez E, Sharma
S and Innocente SA: Repression of IRF-4 target genes in human T
cell leukemia virus-1 infection. Oncogene. 21:6751–6765. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Xu DS, Zhao LJ, Valle LD, Miklossy J and
Zhang LW: Interferon regulatory factor 4 is involved in
Epstein-Barr Virus-mediated transformation of human B lymphocytes.
J Virol. 82:6251–6258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Xu D, Meyer F, Ehlers E, Blasnitz L and
Zhang L: Interferon regulatory factor 4 (IRF-4) targets IRF-5 to
regulate Epstein-Barr virus transformation. J Biol Chem.
286:18261–18267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Barnes BJ, Kellum MJ, Pinder KE, Frisancho
JA and Pitha PM: Interferon regulatory factor 5, a novel mediator
of cell cycle arrest and cell death. Cancer Res. 63:6424–6431.
2003.PubMed/NCBI
|
|
12.
|
Deng M and Daley GQ: Expression of
interferon consensus sequence binding protein induces potent
immunity against BCR/ABL-induced leukemia. Blood. 97:3491–3497.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bailey CM, Khalkhali-Ellis Z, Kondo S,
Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC
and Hendrix MJ: Mammary serine protease inhibitor (Maspin) binds
directly to interferon regulatory factor 6: identification of a
novel serpin partnership. J Biol Chem. 280:34210–34217. 2005.
View Article : Google Scholar
|
|
14.
|
Zhao Y, Xu DS, Jiang YJ and Zhang LW: Dual
functions of interferon regulatory factors 7C in Epstein-Barr
virus-mediated transformation of human B lymphocytes. PLoS One.
5:e94592010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Itoh S, Harada H, Nakamura Y, White R and
Taniguchi T: Assignment of the human interferon regulatory factor-1
(IRF1) gene to chromosome 5q23-q31. Genomics. 10:1097–1099. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Willman CL, Sever CE, Pallavicini MG,
Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC and
List AF: Deletion of IRF-1, mapping to chromosome 5q31.1, in human
leukemia and preleukemic myelodysplasia. Science. 259:968–971.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ogasawara S, Tamura G, Maesawa C, Suzuki
Y, Ishida K, Satoh N, Uesugi N, Saito K and Satodate R: Common
deleted region on the long arm of chromosome 5 in esophageal
carcinoma. Gastroenterology. 110:52–57. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Tamura G, Ogasawara S, Nishizuka S, Sakata
K, Maesawa C, Suzuki Y, Terashima M, Saito K and Satodate R: Two
distinct regions of deletion on the long arm of chromosome 5 in
differentiated adenocarcinomas of the stomach. Cancer Res.
56:612–615. 1996.PubMed/NCBI
|
|
19.
|
Nozawa H, Oda E, Ueda S, Tamura G, Maesawa
C, Muto T, Taniguchi T and Tanaka N: Functionally inactivating
point mutation in the tumor-suppressor IRF-1 gene identified in
human gastric cancer. Int J Cancer. 77:522–527. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Cavalli LR, Riggins RB, Wang A, Clarke R
and Haddad BR: Frequent loss of heterozygosity at the interferon
regulatory factor-1 gene locus in breast cancer. Breast Cancer Res
Treat. 121:227–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Bouker KB, Skaar TC, Harburger DS, Riggins
RB, Fernandez DR, Zwart A and Clarke R: The A4396G polymorphism in
interferon regulatory factor 1 is frequently expressed in breast
cancer cell lines. Cancer Genet Cytogenet. 175:61–64. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Falini B, Mecucci C, Tiacci E, Alcalay M,
Rosati R, Pasqualucci L, Starza R, Diverio D, Colombo E, Santucci
A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P,
Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG
and Martelli MF: Cytoplasmic nucleophosmin in acute myelogenous
leukemia with a normal karyotype. N Engl J Med. 352:254–266. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kondo T, Minamino N, Nagamura-Inoue T,
Matsumoto M, Taniguchi T and Tanaka N: Identification and
characterization of nucleophosmin/B23/numatrin which binds the
anti-oncogenic transcription factor IRF-1 and manifests oncogenic
activity. Oncogene. 15:1275–1281. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Harada H, Kondo T, Ogawa S, Tamura T,
Kitagawa M, Tanaka N, Lamphier MS, Hirai H and Taniguchi T:
Accelerated exon skipping of IRF-1 mRNA in human
myelodysplasia/leukemia; a possible mechanism of tumor suppressor
inactivation. Oncogene. 9:3313–3320. 1994.PubMed/NCBI
|
|
25.
|
Tzoanopoulos D, Speletas M, Arvanitidis K,
Veiopoulou C, Kyriaki S, Thyphronitis G, Sideras P, Kartalis G and
Ritis K: Low expression of interferon regulatory factor-1 and
identification of novel exons skipping in patients with chronic
myeloid leukaemia. Br J Haematol. 119:46–53. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Park JS, Kim EJ, Kwon HJ, Hwang ES,
Namkoong SE and Um SJ: Inactivation of interferon regulatory
factor-1 tumor suppressor protein by HPV E7 oncoprotein.
Implication for the E7-mediated immune evasion mechanism in
cervical carcinogenesis. J Biol Chem. 275:6764–6769. 2000.
View Article : Google Scholar
|
|
27.
|
Junsoo P, Kim K, Lee EJ, Seo YJ, Lim SN,
Park K, Rho SB, Lee SH and Lee JH: Elevated level of SUMOylated
IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc
Natl Acad Sci USA. 104:17028–17033. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tamura T, Yanai H, Savitsky D and
Taniguchi T: The IRF family transcription factors in immunity and
oncogenesis. Annu Rev Immunol. 26:535–584. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Takaoka A, Tamura T and Taniguchi T:
Interferon regulatory factor family of transcription factors and
regulation of oncogenesis. Cancer Sci. 99:467–478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Tanaka N, Ishihara M, Kitagawa M, Harada
H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW and
Taniguchi T: Cellular commitment to oncogene-induced transformation
or apoptosis is dependent on the transcription factor IRF-1. Cell.
77:829–839. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Passioura T, Dolnikov A, Shen S and
Symonds G: N-ras induced growth suppression of myeloid cells is
mediated by IRF-1. Cancer Res. 65:797–804. 2005.PubMed/NCBI
|
|
32.
|
Nozawa H, Oda E, Nakao K, Ishihara M, Ueda
S, Yokochi T, Ogasawara K, Nakatsuru Y, Shimizu S, Ohira Y, Hioki
K, Aizawa S, Ishikawa T, Katsuki M, Muto T, Taniguchi T and Tanaka
N: Loss of transcription factor IRF-1 affects tumor susceptibility
in mice carrying the Ha-ras transgene or nullizygosity for p53.
Genes Dev. 13:1240–1245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Romeo G, Fiorucci G, Chiantore MV,
Percario ZA, Vannucchi S and Affabris E: IRF-1 as a negative
regulator of cell proliferation. J Interferon Cytokine Res.
22:39–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Benech P, Vigneron M, Peretz D, Revel M
and Chebath J: Interferon-responsive regulatory elements in the
promoter of the human 2′,5′-oligo(A)synthetase gene. Mol Cell Biol.
7:4498–4504. 1987.
|
|
35.
|
Takikawa O, Kuroiwa T, Yamazaki F and Kido
R: Mechanism of interferon-γ action. Characterization of
indoleamine 2,3-dioxygenase in cultured human cells induced by
interferon-γ and evaluation of the enzyme-mediated tryptophan
degradation in its anticellular activity. J Biol Chem.
263:2041–2048. 1988.
|
|
36.
|
Kirchhoff S, Koromilas AE, Schaper F,
Grashoff M, Sonenberg N and Hauser H: IRF-1 induced cell growth
inhibition and interferon induction requires the activity of the
protein kinase PKR. Oncogene. 11:439–445. 1995.PubMed/NCBI
|
|
37.
|
Pamment J, Ramsay E, Kelleher M, Dornan D
and Ball KL: Regulation of the IRF-1 tumour modifier during the
response to genotoxic stress involves an ATM-dependent signalling
pathway. Oncogene. 21:7776–7785. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Tan RS, Taniguchi T and Harada H:
Identification of the lysyl oxidase gene as target of the
antioncogenic transcription factor, IRF-1 and its possible role in
tumor suppression. Cancer Res. 56:2417–2421. 1996.PubMed/NCBI
|
|
39.
|
Horiuchi M, Yamada T, Hayashida W and Dzau
VJ: Interferon regulatory factor-1 up-regulates angiotensin II type
2 receptor and induces apoptosis. J Biol Chem. 272:1952–1958. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Clarke N, Jimenez AM, Voltz E and
Gronemeyer H: Tumor suppressor IRF-1 mediates retinoid and
interferon anticancer signaling to death ligand TRAIL. EMBO J.
23:3051–3060. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Chin YE, Kitagawa M, Kuida K, Flavell RA
and Fu XY: Activation of the STAT signaling pathway can cause
expression of caspase 1 and apoptosis. Mol Cell Biol. 17:5328–5337.
1997.PubMed/NCBI
|
|
42.
|
Sancéau J, Hiscott J, Delattre O and
Wietzerbin J: IFN-beta induces serine phosphorylation of Stat-1 in
Ewing’s sarcoma cells and mediates apoptosis via induction of IRF-1
and activation of caspase-7. Oncogene. 19:3372–3383.
2000.PubMed/NCBI
|
|
43.
|
Ruiz C, Ruiz AC, Rodriguez A, Ortiz G,
Redondo JM and López A: The up-regulation of human caspase-8 by
interferon-gamma in breast tumor cells requires the induction and
action of the transcription factor interferon regulatory factor-1.
J Biol Chem. 279:19712–19720. 2004. View Article : Google Scholar
|
|
44.
|
Jeay S, Pianetti S, Kagan HM and
Sonenshein GE: Lysyl oxidase inhibits ras-mediated transformation
by preventing activation of NF-κB. Mol Cell Biol. 23:2251–2263.
2003.PubMed/NCBI
|
|
45.
|
Kroger A, Dallugge A, Kirchhoff S and
Hauser H: IRF-1 reverts the transformed phenotype of oncogenically
transformed cells in vitro and in vivo. Oncogene. 22:1045–1056.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Kroger A, Stirnweiss A, Pulverer JE,
Klages, Grashoff M, Reimann J and Hauser H: Tumor suppression by
IFN regulatory factor-1 is mediated by transcriptional
down-regulation of cyclin D1. Cancer Res. 67:2972–2981. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Pizzoferrato E, Liu Y, Gambotto A,
Armstrong MJ, Stang MT, Gooding WE, Alber SM, Shand SH, Watkins SC
and Storkus WJ: Ectopic expression of interferon regulatory
factor-1 promotes human breast cancer cell death and results in
reduced expression of survivin. Cancer Res. 64:8381–8388. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Frontini M, Vijayakumar M, Garvin A and
Clarke N: A ChIP-chip approach reveals a novel role for
transcription factor IRF1 in the DNA damage response. Nucleic Acids
Res. 37:1073–1085. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Walsh T and King MC: Ten genes for
inherited breast cancer. Cancer Cell. 11:103–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Seal S, Thompson D, Renwick A, Elliott A,
Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K,
North B, McGuffog L, Evans DG, Eccles D; Breast Cancer
Susceptibility Collaboration (UK); Easton DF, Stratton MR and
Rahman N: Truncating mutations in the Fanconi anemia J gene BRIP1
are low penetrance breast cancer susceptibility alleles. Nat Genet.
38:1239–1241. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Harada H, Kitagawa M, Tanaka N, Yamamoto
H, Harada K, Ishihara M and Taniguchi T: Anti-oncogenic and
oncogenic potentials of interferon regulatory factors-1 and -2.
Science. 259:971–974. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Xie RL, Gupta S, Miele A, Shiffman D,
Stein JL, Stein GS and van Wijnen AJ: The tumor suppressor
interferon regulatory factor 1 interferes with SP1 activation to
repress the human CDK2 promoter. J Biol Chem. 278:26589–26596.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Mori K, Yoshida K, Tani J, Nakagawa Y,
Hoshikawa S and Ito S: Double-stranded RNA-induced interferon
regulatory factor-1 gene expression in FRTL-5 rat thyroid cells.
Mol Cell Endocrinol. 84:77–86. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Wang J, Zhang WJ, Zhang YS, Chen Y, Zou B,
Jiang B, Pang R, Gu Q, Qiao L, Lan HY, Kung HF and Wong BC: c-Jun
N-terminal kinase (JNK1) upregulates XIAP-associated factor 1
(XAF1) through interferon regulatory factor 1 (IRF-1) in
gastrointestinal cancer. Carcinogenesis. 30:222–229. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Nguyen H, Lin R and Hiscott J: Activation
of multiple growth regulatory genes following inducible expression
of IRF-1 or IRF/RelA fusion proteins. Oncogene. 15:1425–1435. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Savitsky D, Tamura T, Yanai H and
Taniguchi T: Regulation of immunity and oncogenesis by the IRF
transcription factor family. Cancer Immunol Immunother. 59:489–510.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Strasser A, Harris AW, Jacks T and Cory S:
DNA damage can induce apoptosis in proliferating lymphoid cells via
p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:329–339.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Tamura T, Ishihara M, Lamphier MS, Tanaka
N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S and Taniguchi T:
An IRF-1-dependent pathway of DNA damage-induced apoptosis in
mitogen-activated T lymphocytes. Nature. 376:596–599. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Bowie ML, Ibarra C and Seewalt VL: IRF-1
promotes apoptosis in p53-damaged basal-type human mammary
epithelial cells: a model for early basal-type mammary
carcinogenesis. Adv Exp Med Biol. 617:367–374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Gao J, Senthil M, Ren B, Yan J, Xing Q, Yu
J, Zhang L and Yim JH: IRF-1 transcriptionally upregulates PUMA,
which mediates the mitochondrial apoptotic pathway in IRF-1-induced
apoptosis in cancer cells. Cell Death Differ. 17:699–709. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Lallemand C, Palmieri M, Blanchard B,
Meritet JF and Tovey MG: GAAP-1: a transcriptional activator of p53
and IRF-1 possesses proapoptotic activity. EMBO Rep. 3:153–158.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Kim EJ, Lee JM, Namkoong SE, Um SJ and
Park JS: Interferon regulatory factor-1 mediates
interferon-gamma-induced apoptosis in ovarian carcinoma cells. J
Cell Biochem. 85:369–380. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Fulda S and Debatin KM: IFN gamma
sensitizes for apoptosis by upregulating caspase-8 expression
through the Stat1 pathway. Oncogene. 21:2295–2308. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Bouker KB, Skaar TC, Riggins R, Harburger
DS, Fernandez DR, Zwart A, Wang A and Clarke R: Interferon
regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in
breast cancer associated with caspase activation and induction of
apoptosis. Carcinogenesis. 26:1527–1535. 2005. View Article : Google Scholar
|
|
65.
|
De Ambrosis A, Casciano I, Croce M, Pagnan
G, Radic L, Banelli B, Di Vinci A, Allemanni G, Tonini GP, Ponzoni
M, Romani M and Ferrini S: An interferon-sensitive response element
is involved in constitutive caspase-8 gene expression in
neuroblastoma cells. Int J Cancer. 120:39–47. 2007.PubMed/NCBI
|
|
66.
|
Tomita Y, Bilim V, Hara N, Kasahara T and
Takahashi K: Role of IRF-1 and caspase-7 in IFN-gamma enhancement
of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J
Cancer. 104:400–408. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Park SY, Seol JW, Lee YJ, Cho JH, Kang HS
and Kim IS: IFN-gamma enhances TRAIL-induced apoptosis through
IRF-1. Eur J Biochem. 271:4222–4228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Negishi H, Fujita Y, Yanai H, Sakaguchi S,
Ouyang X, Shinohara M, Takayanagi H, Ohba Y, Taniguchi T and Honda
K: Evidence for licensing of IFN-gamma-induced IFN regulatory
factor 1 transcription factor by MyD88 in toll-like receptor
dependent gene induction program. Proc Natl Acad Sci USA.
103:15136–15141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Taki S, Sato T, Ogasawara K, Fukuda T,
Sato M, Hida S, Suzuki G, Mitsuyama M, Shin EH, Kojima S, Taniguchi
T and Asano Y: Multistage regulation of Th1-type immune responses
by the transcription factor IRF-1. Immunity. 6:673–679. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Trinchieri G: Biology of natural killer
cells. Adv Immunol. 47:187–376. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Ogasawara K, Hida S, Azimi N, Tagaya Y,
Sato T, Yokochi T, Waldmann TA, Taniguchi T and Taki S: Requirement
for IRF-1 in the microenvironment supporting development of natural
killer cells. Nature. 391:700–703. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Gabriele L, Fragale A, Borghi P, Sestili
P, Stellacci E, Venditti M, Schiavoni G, Sanchez M, Belardelli F
and Battistini A: IRF-1 deficiency skews the differentiation of
dendritic cells toward plasmacytoid and tolerogenic features. J
Leukoc Biol. 80:1500–1511. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Matsuyama T, Kimura T, Kitagawa M, Pfeffer
K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K and
Wakeham A: Targeted disruption of IRF-1 or IRF-2 results in
abnormal type I IFN gene induction and aberrant lymphocyte
development. Cell. 75:83–97. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Reis LF, Ruffner H, Stark G, Aguet M and
Weissmann C: Mice devoid of interferon regulatory factor 1 (IRF-1)
show normal expression of type I interferon genes. EMBO J.
13:4798–4806. 1994.PubMed/NCBI
|
|
75.
|
White LC, Wright KL, Felix NJ, Ruffner H,
Reis LF, Pine R and Ting JP: Regulation of LMP2 and TAP1 genes by
IRF-1 explains the paucity of CD8 + T cells in IRF-1−/− mice.
Immunity. 5:365–376. 1996.PubMed/NCBI
|
|
76.
|
Penninger JM, Sirard C, Mittrucker HW,
Chidgey A, Kozieradzki I, Nghiem M, Hakem A, Kimura T, Timms E,
Boyd R, Taniguchi T, Matsuyama T and Mak TW: The interferon
regulatory transcription factor IRF-1 controls positive and
negative selection of CD8+ thymocytes. Immunity. 7:243–254.
1997.PubMed/NCBI
|
|
77.
|
Lohoff M, Ferrick D, Mittrucker HW, Duncan
GS, Bischof S, Rollinghoff M and Mak TW: Interferon regulatory
factor-1 is required for a T helper 1 immune response in vivo.
Immunity. 6:681–689. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Wiwanitkit V: Interaction between
interferon regulatory factor-1 and human papillomavirus E7 oncogene
in cervical cancer: an ontology study. Taiwan J Obstet Gynecol.
48:138–141. 2009. View Article : Google Scholar
|
|
79.
|
MacMicking J, Xie QW and Nathan C: Nitric
oxide and macrophage function. Annu Rev Immunol. 15:323–350. 1997.
View Article : Google Scholar : PubMed/NCBI
|
